These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21883375)

  • 1. Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism.
    Ruffmann C; Giaccone G; Canesi M; Bramerio M; Goldwurm S; Gambacorta M; Rossi G; Tagliavini F; Pezzoli G
    Neuropathol Appl Neurobiol; 2012 Jun; 38(4):382-6. PubMed ID: 21883375
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinsonism, Lrrk2 G2019S, and tau neuropathology.
    Rajput A; Dickson DW; Robinson CA; Ross OA; Dächsel JC; Lincoln SJ; Cobb SA; Rajput ML; Farrer MJ
    Neurology; 2006 Oct; 67(8):1506-8. PubMed ID: 17060589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.
    Munhoz RP; Teive HA; Francisco AN; Raskin S; Rogaeva E
    Mov Disord; 2009 Apr; 24(5):791-2; author reply 792. PubMed ID: 19012346
    [No Abstract]   [Full Text] [Related]  

  • 4. Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.
    Clarimón J; Pagonabarraga J; Paisán-Ruíz C; Campolongo A; Pascual-Sedano B; Martí-Massó JF; Singleton AB; Kulisevsky J
    Mov Disord; 2008 Mar; 23(4):518-23. PubMed ID: 18098275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.
    Schüpbach M; Lohmann E; Anheim M; Lesage S; Czernecki V; Yaici S; Worbe Y; Charles P; Welter ML; Pollak P; Dürr A; Agid Y; Brice A
    Mov Disord; 2007 Jan; 22(1):119-22. PubMed ID: 17080443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy.
    Ozelius LJ; Foroud T; May S; Senthil G; Sandroni P; Low PA; Reich S; Colcher A; Stern MB; Ondo WG; Jankovic J; Huang N; Tanner CM; Novak P; Gilman S; Marshall FJ; Wooten GF; Chelimsky TC; Shults CW;
    Mov Disord; 2007 Mar; 22(4):546-9. PubMed ID: 17230458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial aggregation of parkinsonism in progressive supranuclear palsy.
    Donker Kaat L; Boon AJ; Azmani A; Kamphorst W; Breteler MM; Anar B; Heutink P; van Swieten JC
    Neurology; 2009 Jul; 73(2):98-105. PubMed ID: 19458322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
    Santos-Rebouças CB; Abdalla CB; Baldi FJ; Martins PA; Corrêa JC; Gonçalves AP; Cunha MS; Borges MB; Pereira JS; Laks J; Pimentel MM
    Genet Test; 2008 Dec; 12(4):471-3. PubMed ID: 19072560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 gene and tremor-dominant parkinsonism.
    Haugarvoll K; Uitti RJ; Farrer MJ; Wszolek ZK
    Arch Neurol; 2006 Sep; 63(9):1346-7. PubMed ID: 16966525
    [No Abstract]   [Full Text] [Related]  

  • 10. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.
    González-Fernández MC; Lezcano E; Ross OA; Gómez-Esteban JC; Gómez-Busto F; Velasco F; Alvarez-Alvarez M; Rodríguez-Martínez MB; Ciordia R; Zarranz JJ; Farrer MJ; Mata IF; de Pancorbo MM
    Parkinsonism Relat Disord; 2007 Dec; 13(8):509-15. PubMed ID: 17540608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olfactory heterogeneity in LRRK2 related Parkinsonism.
    Silveira-Moriyama L; Munhoz RP; de J Carvalho M; Raskin S; Rogaeva E; de C Aguiar P; Bressan RA; Felicio AC; Barsottini OG; Andrade LA; Chien HF; Bonifati V; Barbosa ER; Teive HA; Lees AJ
    Mov Disord; 2010 Dec; 25(16):2879-83. PubMed ID: 20818658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
    Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
    J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
    van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I;
    Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign tremulous parkinsonism in a patient with dardarin mutation.
    Rizzo G; Marconi S; Capellari S; Scaglione C; Martinelli P
    Mov Disord; 2009 Jul; 24(9):1399-401. PubMed ID: 19373934
    [No Abstract]   [Full Text] [Related]  

  • 15. [LRRK2 is a major gene in North African parkinsonism].
    Lesage S; Dürr A; Brice A
    Med Sci (Paris); 2006 May; 22(5):470-1. PubMed ID: 16687108
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel LRRK2 mutations in Parkinsonism.
    Trinh J; Guella I; McKenzie M; Gustavsson EK; Szu-Tu C; Petersen MS; Rajput A; Rajput AH; McKeown M; Jeon BS; Aasly JO; Bardien S; Farrer MJ
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1119-21. PubMed ID: 26213354
    [No Abstract]   [Full Text] [Related]  

  • 17. LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation.
    Marras C; Klein C; Lang AE; Wakutani Y; Moreno D; Sato C; Yip E; Munhoz RP; Lohmann K; Djarmati A; Bi A; Rogaeva E
    Neurobiol Aging; 2010 Apr; 31(4):721-2. PubMed ID: 18644660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autosomal dominant tauopathy with parkinsonism and central hypoventilation.
    Omoto M; Suzuki S; Ikeuchi T; Ishihara T; Kobayashi T; Tsuboi Y; Ogasawara J; Koga M; Kawai M; Iwaki T; Kanda T
    Neurology; 2012 Mar; 78(10):762-4. PubMed ID: 22357714
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
    Zimprich A; Biskup S; Leitner P; Lichtner P; Farrer M; Lincoln S; Kachergus J; Hulihan M; Uitti RJ; Calne DB; Stoessl AJ; Pfeiffer RF; Patenge N; Carbajal IC; Vieregge P; Asmus F; Müller-Myhsok B; Dickson DW; Meitinger T; Strom TM; Wszolek ZK; Gasser T
    Neuron; 2004 Nov; 44(4):601-7. PubMed ID: 15541309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.
    Ludolph AC; Kassubek J; Landwehrmeyer BG; Mandelkow E; Mandelkow EM; Burn DJ; Caparros-Lefebvre D; Frey KA; de Yebenes JG; Gasser T; Heutink P; Höglinger G; Jamrozik Z; Jellinger KA; Kazantsev A; Kretzschmar H; Lang AE; Litvan I; Lucas JJ; McGeer PL; Melquist S; Oertel W; Otto M; Paviour D; Reum T; Saint-Raymond A; Steele JC; Tolnay M; Tumani H; van Swieten JC; Vanier MT; Vonsattel JP; Wagner S; Wszolek ZK;
    Eur J Neurol; 2009 Mar; 16(3):297-309. PubMed ID: 19364361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.